With Z-codes, Will Other Payers Follow UnitedHealthcare’s Lead?

By Virchow | From the Volume XXX, No. 11 – July 31, 2023 Issue

EDITOR’S NOT…

Read More

---

Issues Encountered with Anthem’s Pre-approval

By Joseph Burns | From the Volume XXIV No. 11 – August 7, 2017 Issue

CEO SUMMARY: Since Anthem and AIM Specialty Health began a prior-authorization program for genetic testing July 1, a Northeast lab has not had any genetic tests approved through the new system. Physicians told the lab that the steps required for prior authorization were disruptive. Those …

Read More

---

Congress Seems Ready to Tackle LDT Regulation

By R. Lewis Dark | From the Volume XXIV No. 6 – April 24, 2017 Issue

RECENT DEVELOPMENTS SIGNAL THAT THE FIGHT over FDA regulation of laboratory-developed tests (LDTs) is about to intensify. Last month, two Congressional representatives announced a new bill about LDTs that they said was a “discussion draft.” The bill is titled the “Diagnostic Accuracy and Innova…

Read More

---

Clinical Labs Bidding Up Lab Director Salaries

By Joseph Burns | From the Volume XXIV No. 3 – February 21, 2017 Issue

CEO SUMMARY: There’s great news for pathologists and PhDs with expertise in molecular and genetic testing. Salaries are on the rise as more clinical labs build up their molecular and genetic testing programs and need talent to implement and supervise this activity. One experienced medic…

Read More

---

Market Price Data Sample from: Molecular/Genetic Labs

By Robert Michel | From the Volume XXIII No. 15 – November 7, 2016 Issue

Here is the market price data for molecular and genetic labs from XIFIN Inc. Lâle White, Founder and CEO of XIFIN, discusses the data with THE DARK REPORT. EDITOR: When you did this analysis of molecular and genetic…

Read More

---

Genetic Testing Lab Finds Payers Respond To Education on Test Utility

By Joseph Burns | From the Volume XXIII No. 8 – June 13, 2016 Issue

CEO SUMMARY: In recent years, insurers have raised the bar and become much tougher when making coverage and reimbursement decisions for molecular assays, genomic, and genetic tests. Yet several lab testing companies are having good success at demonstrating the validity and clinical utilit…

Read More

---

Understanding the Future Of Laboratory Medicine

By Robert Michel | From the Volume XXIII No. 4 – March 21, 2016 Issue

CEO SUMMARY: Healthcare’s transformation is now far enough along that most clinical labs and pathology groups are either feeling the financial pain or are excitedly developing ways to deliver more value from lab testing services. On April 26-27, at the 21st annual …

Read More

---

New Company Tracks Details and Prices For 60,000 Molecular and Genetic Tests

By Joseph Burns | From the Volume XXIII, No. 1 – January 19, 2016 Issue

CEO SUMMARY: Advances in the speed, accuracy, and cost of next-generation gene sequencing making it possible for clinical labs to create thousands of new tests. How many new tests? NextGxDx, an information technology company, says the nation’s clinical laboratories are introducing new m…

Read More

---

Some Labs Report Faster Pay For Molecular, Genetic Tests

By Joseph Burns | From the Volume XXII NO. 8 – June 1, 2015 Issue

DURING RECENT MONTHS, some labs are reporting improvement in how their claims for certain molecular and genetic tests are being reimbursed. This is progress from the financial crises experienced during 2013 for many labs performing molecular and genetic tests. Disruption in these payments wa…

Read More

---

NeoGenomics to Acquire Clarient for $275 Million

By Joseph Burns | From the Volume XXII No. 15 – October 26, 2015 Issue

CEO SUMMARY: In a surprise move that further consolidates national anatomic pathology services, NeoGenomics will acquire Clarient Inc., from General Electric Healthcare. General Electric is getting cash, and preferred and common stock. The two companies announced plans to pursue integrate…

Read More

---